Comment from Ohio Right to Life
AnonymousOpposeAdvocacy
Summary: Ohio Right to Life, an advocacy organization, opposes the proposed action because it would prevent the FDA from restricting access to or increasing regulations on mifepristone. The organization argues that the drug is unsafe, citing high rates of serious adverse events and deaths, and calls for a reconsideration of the research data supporting its use.
Title: Public Comment on FDA-2025-P-2162
To Whom It May Concern:
On behalf of Ohio Right to Life (ORTL), I am writing in response to the FDA’s consideration of FDA-2025-P-2162 that would “…require the FDA to take no action to reduce patient access to mifepristone and/or increase the burdens associated prescribing or dispensing mifepristone.”
Ohio Right to Life remains intrinsically opposed to the use of Mifepristone and any effort to make this drug more accessible and less regulated. Continued evidence continues to point to the misleading data that surrounds this drug that portray it to be a safe option for women. Currently, 36 documented deaths have been reported to the FDA in addition to thousands of adverse events linked to mifepristone use. Most recently a 2024 Ethics and Public Policy Center report found an 11% serious adverse event rate in U.S. insurance claims data—far higher than the 0.5% often cited by abortion advocates.
As peer reviewed research continues to show significantly higher complication rates for chemical abortions compared to surgical abortions, now is clearly the time to reconsider the research findings, reporting metrics, and to question the data that has been shown to be fraudulent. The ORTL is confident that in doing so, access, prescription and dispensary of mifepristone will be halted accordingly.
Thank you for your attention to this issue and for your continued commitment to patient health and safety.
Sincerely,
Carrie Snyder
Executive Director
Ohio Right to Life